Table 2 Summary of the four TNBC classification systems
From: Classifications of triple-negative breast cancer: insights and current therapeutic approaches
Sub-items | Lehmann | Burstein | Jézéquel | FUSCC |
|---|---|---|---|---|
Data source | TCGA | TCGA+ patients | TCGA+ patients | TCGA+ patients |
Initial classification criteria | Transcriptional groups profiling | RNA and DNA genomic profiling | Therapeutic outcomes | Multiple-omic groups |
Intentional Therapy | NACT | No | No | No |
Subtype-relate therapy | Yes | Yes | Yes | Yes |
External validation | Yes | Yes | Yes | Yes |
Gene mutation | Yes | Yes | Yes | Yes |
Pathways mutation | Yes | Yes | Yes | Yes |
Metastasis preference | Yes | No | No | Yes |
Metabolic characteristics | No | No | Yes | Yes |
Histological differences | Yes | No | No | No |
IHC validation | Predicted | Yes | Yes | Yes |
Local clinical data | No | Yes | Yes | Yes |
Adverse effects | Not given | Not given | Yes | Yes |
Relative cell lines | Yes | No | No | Yes |
Characteristics | More transcriptional; cellular details | More epigenetic analysis | More immune modulation details More external validation details | Asian patients Multi-omics data More mesenchymal-like details |